GPRS for psychiatric and metabolic traits were generated based on discovery GWAS meta-analysis results from large international consortia (see supplemental methods for detailed description). Results from the Psychiatric Genomics Consortium (PGC) were used to derive GPRS for MDD(4) (~8K cases, ~8K controls), bipolar disorder(33) (BIP; ~7K, ~9K controls) and schizophrenia(34) (SCZ2; ~36K cases, ~113K controls). Discovery GWAS meta-analyses for metabolic traits were from GIANT Consortium(35) for BMI (~120K samples), Dehghan et al.(36) for C-reactive protein (CRP; ~70K samples) and Teslovich et al.(37) for triglycerides (TR; ~100K). Since NESDA and NTR samples contributed to MDD and BMI discovery GWAS, meta-analyses for these traits were performed with the Dutch GWAS cohort excluded in order to remove any chance of overlap between discovery and target samples. For all traits, eight sets of independent SNPs were selected based on significance thresholds (Pt <0.0001, <0.001, <0.005, <0.01, <0.05, <0.1, <0.5, <1) of the discovery samples associations. GPRS were calculated as the number of scores alleles weighted by effect sizes from the discovery statistics using PLINKv1.07(38) and were standardized to aid interpretation of the results. Number of SNPs included in the GPRS according to Pts are reported in Table 1.
